Montelukast Qualigen

Montelukast, the active ingredient in Montelukast Qualigen, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in patients requiring maintenance therapy and is prescribed by healthcare professionals.

GNH USA supplies Montelukast Qualigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements. Our distribution network ensures reliable access across multiple regions.

Montelukast is a leukotriene receptor antagonist used in the management of respiratory and allergic conditions.

- Asthma: reduces frequency of attacks and improves overall control in maintenance therapy. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity in susceptible individuals.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported in clinical use. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Abdominal pain: occasional stomach discomfort or cramps. - Cough: transient cough without underlying infection.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Allergic reactions: rash, urticaria, or angioedema. - Hepatotoxicity: abnormal liver function tests or hepatitis.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: Category B, use only if benefit outweighs potential risk. - Breastfeeding: Small amounts excreted in milk; weigh benefits against infant exposure. - Hepatic impairment: Use with caution; monitor liver function in patients with liver disease. - Concomitant asthma therapy: Do not discontinue inhaled corticosteroids without medical guidance. - Neuropsychiatric monitoring: Observe patients for mood changes or suicidal ideation. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: enzyme induction may reduce montelukast plasma levels. - Rifampin: strong CYP3A4 inducer can lower drug exposure.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): may increase risk of neuropsychiatric side effects. - Antihistamines: additive sedation is uncommon but monitor patient response. - Warfarin: occasional reports of altered INR; check coagulation parameters. - Oral contraceptives: may slightly increase montelukast levels; no dose adjustment usually needed.